Epigenomics AG / Veröffentlichung der Gesamtzahl der Stimmrechte 28.02.2014 10:15 Veröffentlichung der Gesamtzahl der Stimmrechte nach § 26a WpHG, übermittelt durch die DGAP – ein Unternehmen der EQS Group AG. Für den Inhalt der Mitteilung ist der Emittent verantwortlich. ————————————————————————— Hiermit teilt die Epigenomics AG mit, dass die Gesamtzahl der Stimmrechte am Ende des Monats […]
Year: 2014
28. February 2014
Epigenomics AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 26a WpHG mit dem Ziel der europaweiten Verbreitung
Read more
26. February 2014
Epigenomics AG: Epigenomics AG Reports Preliminary Results and Highlights for the Year Ended December 31, 2013
Epigenomics AG / Key word(s): Preliminary Results 26.02.2014 / 08:30 Revenue improved by 53% to EUR 1.6 million (2012: EUR 1.0 million) Net loss reduced by 39% to EUR 7.4 million (2012: EUR 12.2 million) through cost reductions; cash consumption of EUR 6.5 million reduced by 40% (2012: EUR 10.9 million) Decisive steps forward in […]
10. February 2014
Epigenomics AG: Epigenomics Further Strengthens Intellectual Property Coverage for Epi proColon in the U.S. and in China
Epigenomics AG / Key word(s): Patent 10.02.2014 / 11:30 Patents cover detection of colorectal cancer with Septin9 biomarker Berlin (Germany) and Germantown, MD (U.S.A.), February 10, 2014 – Epigenomics AG (Frankfurt Prime Standard: ECX; OTCQX: EPGNY), the German-American cancer molecular diagnostics company, today announced that the Company was granted key Intellectual Property (IP) rights related […]
06. February 2014
Epigenomics AG: Epigenomics announces Date for the FDA Advisory Committee Meeting to Review Epi proColon and for the Publication of Preliminary Financial Results 2013
Epigenomics AG / Key word(s): Miscellaneous 06.02.2014 / 14:00 Berlin (Germany) and Germantown, MD (U.S.A.), February 06, 2014 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTC: EPGNY), the German-American cancer molecular diagnostics company, today announced that the date for the FDA Advisory Committee meeting for Epigenomics’ blood-based colorectal cancer screening test Epi proColon(R) was published […]
10. January 2014
Epigenomics AG: Epigenomics Begins Trading on OTCQX Marketplace in the U.S.
Epigenomics AG / Key word(s): Miscellaneous 10.01.2014 / 10:00 Press release Epigenomics Begins Trading on OTCQX Marketplace in the U.S. – BNY Mellon to act as Principal American Liaison (PAL) for Epigenomics on OTCQX – Epigenomics’ ADRs to start trading under ticker symbol EPGNY today Berlin, Germany, and Germantown, MD, U.S.A., January 10, 2014 – […]
09. January 2014
Epigenomics AG: Epigenomics signs licensing and supply agreement with Kindstar for Epi proLung in China
Epigenomics AG / Key word(s): Agreement 09.01.2014 / 08:30 Berlin, Germany, Germantown, MD, U.S.A. and Wuhan and Beijing, China, January 9, 2014 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTC: EPGNY), a German-American cancer molecular diagnostics company, and Wuhan Kindstar Clinical Diagnostics Co. Ltd (Kindstar), a leading Chinese clinical diagnostics company, announced today that both […]